ABLIVA AB NPV revenue breakdown overview

ABLIVA AB NPV revenue for the last year amounted to 1.00 M SEK, the most of which — 137.00 k SEK — came from its highest performing source at the moment, Mitochondrial Diseases, the year earlier bringing 31.00 k SEK. The greatest contribution to the revenue figure was made by Sweden — last year it brought ABLIVA AB NPV 137.00 k SEK, and the year before that — 31.00 k SEK.